Thursday, 15 October 2026European Markets

ROTHSCHILD & CO Stock Slides By 16% In The Last 5 Sessions

Loading stream...

(vianews) - shares of rothschild & co (cac 40: roth.pa) fell by a staggering 16.68% in 5 sessions from €46.45 to €38.70 at 14:07 est on thursday, following the last session's upward trend. cac 40 is jumping 0.36% to €7,353.35, after two successive sessions in a row of gains.

rothschild & co's last close was €46.60, 3.02% below its 52-week high of €48.05.

about rothschild & co

rothschild & co sca provides global advisory, wealth and asset management, and merchant banking services in france, the united kingdom, the channel islands, the americas, rest of europe, switzerland, australia, asia, and internationally. the company offers merger and acquisition, and strategic advisory solutions; debt advisory and restructuring services; and equity advisory services, such as equity capital markets (ecm) advisory, private capital, and investor advisory and marketing services. it also provides wealth management services to successful families, individuals, foundations, and charities; and asset management services comprising bespoke investment management and advisory services to institutional clients, financial intermediaries, and third-party distributors. in addition, the company offers merchant banking services, including corporate private equity, multi strategies, direct lending, and credit management. rothschild & co sca was founded in 1838 and is headquartered in paris, france.

earnings per share

as for profitability, rothschild & co has a trailing twelve months eps of €8.29.

pe ratio

rothschild & co has a trailing twelve months price to earnings ratio of 4.67. meaning, the purchaser of the share is investing €4.67 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.02%.

more news about rothschild & co (roth.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com